Estrella Immunopharma, Inc. (ESLA)
NASDAQ: ESLA · Real-Time Price · USD
1.140
0.00 (0.00%)
May 20, 2026, 4:00 PM EDT - Market closed
Estrella Immunopharma Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for Estrella Immunopharma in the last 12 months.
Price Target: $12 (+952.63%)
Analyst Consensus: n/a
* Price targets were last updated on Feb 9, 2026.
Analyst Ratings
There are currently no analyst ratings available for Estrella Immunopharma.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $8 | Strong Buy | Maintains | $8 | +601.75% | Feb 9, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $16 → $8 | Strong Buy | Maintains | $16 → $8 | +601.75% | Jan 28, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $16 | Strong Buy | Maintains | $16 | +1,303.51% | Nov 3, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $16 | Strong Buy | Maintains | $16 | +1,303.51% | Aug 12, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $16 | Strong Buy | Maintains | $16 | +1,303.51% | Jun 3, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-39.78
from -0.35
EPS Next Year
-32.64
from -39.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -40.95 | -33.60 | ||||||
| Avg | -39.78 | -32.64 | ||||||
| Low | -38.22 | -31.36 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.